Dynamics of the immune response in laboratory animals to the introduction of a protective protein of the cause of respiratory syncytial infection in cattle

Abstract

The authors in the article presented the results of assessing the immune response of guinea pigs using the protective protein of the bovine respiratory syncytial infection virus (RSI), obtained using recombinant E. coli BRSV-F1. The research was carried out in the branch laboratory of veterinary biotechnology and infectious animal diseases of the Vitebsk Order of the Badge of Honor of the State Academy of Veterinary Medicine. The average titer of specific antibodies of guinea pigs to the use of the protective protein of the bovine RSI virus was studied in 9 experimental groups and one control group. Blood sampling was carried out at the beginning of the experiment, before the second immunisation and 14 days after the second immunisation. The average titer of specific antibodies to the use of the protective protein of the bovine RSI virus was determined using an indirect hemagglutination reaction with an erythrocyte diagnosticum containing the bovine respiratory syncytial virus (RSV). With the introduction of samples of the prototype vaccine containing the gene encoding the production of the bovine RSI virus protein: group 1 - whole bacteria E. coli BRSV-F1 with an inducer of protein synthesis IPTG; 2nd, whole bacteria E. coli BRSV-F1 with protein synthesis inducer IPTG + 15% adjuvant IZA-15; 3rd, bacterial lysate E. coli BRSV-F1 with an inducer of protein synthesis IPTG; 4th – E. coli bacterial lysate BRSV-F1 with protein synthesis inducer IPTG + 15% adjuvant IZA-15; 5th - protective protein F1 + 15% adjuvant IZA-15; 6th - protective protein F1 + 2% cellulose, 7th - inactivated bovine RSV (JSC «Belvitunipharm») + 15% adjuvant IZA15; 8th - Hiprabovis 4 vaccines (HIPRA, Spain) and 9th - Bovi-shield Gold FP 5 L5 vaccines (Zoetis, USA) - in the experimental groups, an increase in antibody titer in paired blood sera was noted compared to the control group. From the data obtained, it was concluded that the studied samples of the vaccine prototype containing the gene encoding the production of the bovine RSV protein are not inferior in immunogenic activity to the vaccines Bovishield Gold FP 5 L5 and Hiprabovis 4. Therefore, the protective protein of the bovine RSI virus can be included in the composition of vaccines against this pathology to replace the cultural virus.